635 related articles for article (PubMed ID: 25637943)
61. Using high-content screening technology for studying drug-induced hepatotoxicity in preclinical studies.
Donato MT; Gómez-Lechón MJ; Tolosa L
Expert Opin Drug Discov; 2017 Feb; 12(2):201-211. PubMed ID: 27936962
[TBL] [Abstract][Full Text] [Related]
62. The timing of preclinical toxicological studies: pharmaceutical company approaches to toxicity testing in support of initial clinical investigations.
Parkinson C; Thomas KE; Lumley CE
Regul Toxicol Pharmacol; 1996 Apr; 23(2):162-72. PubMed ID: 8661335
[TBL] [Abstract][Full Text] [Related]
63. Computational toxicology--a tool for early safety evaluation.
Merlot C
Drug Discov Today; 2010 Jan; 15(1-2):16-22. PubMed ID: 19835978
[TBL] [Abstract][Full Text] [Related]
64. Applications of emerging technologies in toxicology and safety assessment.
Reynolds VL
Int J Toxicol; 2005; 24(3):135-7. PubMed ID: 16040564
[TBL] [Abstract][Full Text] [Related]
65. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
Pugsley MK; Curtis MJ; Hayes ES
Handb Exp Pharmacol; 2015; 229():149-203. PubMed ID: 26091640
[TBL] [Abstract][Full Text] [Related]
66. Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society.
Bass AS; Vargas HM; Valentin JP; Kinter LB; Hammond T; Wallis R; Siegl PK; Yamamoto K
J Pharmacol Toxicol Methods; 2011; 64(1):7-15. PubMed ID: 21689769
[TBL] [Abstract][Full Text] [Related]
67. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
[TBL] [Abstract][Full Text] [Related]
68. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
[TBL] [Abstract][Full Text] [Related]
69. Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations.
Cavero I
Expert Opin Drug Saf; 2009 Nov; 8(6):627-47. PubMed ID: 19998526
[TBL] [Abstract][Full Text] [Related]
70. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
Fleuranceau-Morel P
Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
[TBL] [Abstract][Full Text] [Related]
71. Optimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog.
Smith D; Combes R; Depelchin O; Jacobsen SD; Hack R; Luft J; Lammens L; von Landenberg F; Phillips B; Pfister R; Rabemampianina Y; Sparrow S; Stark C; Stephan-Gueldner M
Regul Toxicol Pharmacol; 2005 Mar; 41(2):95-101. PubMed ID: 15698532
[TBL] [Abstract][Full Text] [Related]
72. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
73. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
Kramer JA; Sagartz JE; Morris DL
Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
[TBL] [Abstract][Full Text] [Related]
74. Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how.
Hornberg JJ; Laursen M; Brenden N; Persson M; Thougaard AV; Toft DB; Mow T
Drug Discov Today; 2014 Aug; 19(8):1131-6. PubMed ID: 24368175
[TBL] [Abstract][Full Text] [Related]
75. Repeated "Day 1" FOB testing in ICH S7A safety assessment protocols: The influence of within- and between-session learning.
Gauvin DV; Zimmermann ZJ; Dalton JA; Baird TJ
J Pharmacol Toxicol Methods; 2017; 85():61-72. PubMed ID: 28216425
[TBL] [Abstract][Full Text] [Related]
76. Cardiovascular parameters in anaesthetized guinea pigs: a safety pharmacology screening model.
Hauser DS; Stade M; Schmidt A; Hanauer G
J Pharmacol Toxicol Methods; 2005; 52(1):106-14. PubMed ID: 15961325
[TBL] [Abstract][Full Text] [Related]
77. Toxicologic Pathology Forum: Current Status on the Use of Animal Models of Human Disease in the Pharmaceutical Industry in Japan in Nonclinical Safety Assessment-Opinion Paper.
Tomohiro M; Okabe T; Kimura Y; Kinoshita K; Maeda M; Mitobe Y; Motoyama K; Yonezawa R; Sasaki S; Fujiwara M; Watanabe K
Toxicol Pathol; 2019 Feb; 47(2):108-120. PubMed ID: 30636562
[TBL] [Abstract][Full Text] [Related]
78. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey.
Hammond TG; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Redfern WS; Sullivan AT; Camm AJ
Cardiovasc Res; 2001 Mar; 49(4):741-50. PubMed ID: 11230973
[TBL] [Abstract][Full Text] [Related]
79. Safety biomarkers in preclinical development: translational potential.
Sasseville VG; Mansfield KG; Brees DJ
Vet Pathol; 2014 Jan; 51(1):281-91. PubMed ID: 24091814
[TBL] [Abstract][Full Text] [Related]
80. Origins, practices and future of safety pharmacology.
Bass A; Kinter L; Williams P
J Pharmacol Toxicol Methods; 2004; 49(3):145-51. PubMed ID: 15172010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]